Results 91 to 100 of about 12,163 (174)

Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation [PDF]

, 2011
Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical development for the prevention of stroke in atrial fibrillation (AF). A phase II study was undertaken to evaluate the safety and efficacy of edoxaban in Asian patients with
Lee, TH, Chen, SA, Wen-Ter Lai, Hui-Kyung Jeon, Shih-Ann Chen, Tsong-Hai Lee, Chung, WS, Jeon, HK, Wook-Sung Chung, Chung, N, Hung-Fat Tse, Tse, HF, Lien, LM, Namsik Chung, Li-Ming Lien, Lai, WT   +15 more
core   +1 more source

Pharmacokinetics of Edoxaban in Geriatric Patients with Atrial Fibrillation

Atrial fibrillation affects nearly half of geriatric inpatients, with edoxaban frequently used for stroke prevention. However, geriatric patients are underrepresented in drug trials with edoxaban.
Edwina, Elma, Tournoy, Jos, Foerster, Kathrin, Spriet, Isabel, Van der Linden, Lorenz, Verhamme, Peter, Debruyne, Louise, Vanassche, Thomas, Dreesen, Erwin, Burhenne, Jürgen   +9 more
core   +1 more source

Postoperative D-dimer as a signal of venous thromboembolism in patients receiving Edoxaban after hip or knee arthroplasty

Journal of Pharmaceutical Health Care and Sciences
Background Edoxaban is the only direct-acting oral anticoagulant (DOAC) indicated for preventing venous thromboembolism (VTE) in patients undergoing arthroplasty and can be administered for a short period (1–2 weeks).
Norito Nishiyama, Shiori Iwane, Masayuki Tanaka, Takanori Saito, Toshikazu Tsuji, Noboru Tanigawa   +5 more
doaj   +1 more source

Prevalence, risk characteristics, and prediction of low-dose edoxaban treatment in hospitalized patients: a multicenter, observational cohort study

Frontiers in Pharmacology
BackgroundTreatment with a low-dose non-vitamin K antagonist oral anticoagulant (NOAC) is common among hospitalized patients, and a model to predict the need for such treatment would support individualized interventions.
Shujuan Zhao, Hengfen Dai, Jiaxin Chen, Ming Ni, Wenxing Peng, Xiaoyu Li, Fen Li, Boya Chen, Haixia Cai, Yinping Liu, Song Du   +10 more
doaj   +1 more source

Correlation between blood loss and pharmacodynamic markers in edoxaban-anticoagulated rabbits.

, 2018
Blood loss correlated with (A) anti-FXa activity and (B) unbound edoxaban plasma concentrations. Each data point represents the measurements from an individual rabbit at the end of andexanet infusion (Time 25 minutes) for anti-FXa and unbound edoxaban ...
Janet M. Leeds (346149), John Malinowski (5029931), Polly Pine (5029946), Stanley J. Hollenbach (2720365), Joyce Lin (5029937), John T. Curnutte (5029940), Francis DeGuzman (5029934), Pratikhya Pratikhya (235082), Genmin Lu (5029949), Pamela B. Conley (5029943)   +9 more
core   +1 more source

Edoxaban‐induced enterocolitis: The first case report demonstrating distinct endoscopic and histological features

DEN Open
Direct oral anticoagulants (DOACs), including edoxaban, are widely used for stroke prevention in atrial fibrillation and venous thromboembolism. While gastrointestinal bleeding and diarrhea are recognized adverse effects, DOAC‐induced enterocolitis has ...
Katsuya Endo, Jun Yamada, Tomofumi Katayama, Yuki Yoshino, Daisuke Fukushi, Akinobu Koiwai, Takayuki Kogure, Morihisa Hirota, Kennichi Satoh   +8 more
doaj   +1 more source

Effectiveness and Safety of Dose-Specific DOACs in Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Cardiovascular Therapeutics
Conclusions: This study found that all DOACs provided comparable or superior effectiveness and safety to warfarin. SD apixaban, SD edoxaban, and LD edoxaban achieved a favorable balance between preventing S/SE and MB risk.
Sang-Hyeon Oh, Seunghyun Cheon, Seo-Yong Choi, Young Seo Kim, Han-Gon Choi, Jee-Eun Chung   +5 more
doaj   +1 more source

Pacemaker-associated thrombosis in ongoing therapy with edoxaban tosylate

, 2018
Thromboembolism is a known complication of pacemaker implantation. However, published literature describes only a few cases, in which the events occurred in absence of antithrombotic prophylaxis, not routinely employed for its prevention in current ...
Di Vincenzo, Angelo, Rizzo, Alessandro, Russo, Lucia, Mioni, Roberto   +3 more
core   +1 more source

Edoxaban Safety and Effectiveness in Real-Life Patients with Heart Failure and Atrial Fibrillation: EMAYIC Study

Background/Objectives: Real-world data about clinical characteristics and edoxaban performance in patients with heart failure (HF) and atrial fibrillation (AF) are lacking.
Salguero Bodes, Rafael, Aparici Feal, M. A., García López, M., Sánchez, A. A, Padilla Perez, M., Gaebelt, H. P., Santos, J. L., Arribas Ynsaurriaga, Fernando, Esteban-Fernández, A., EMAYIC Study Investigators   +9 more
core   +1 more source

Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism

Therapeutics and Clinical Risk Management, 2016
Katie B Tellor, Joseph S Van Tuyl, Anastasia L Armbruster Department of Pharmacy Practice, St Louis College of Pharmacy, St Louis, MO, USA Abstract: Edoxaban, a factor Xa inhibitor, was approved by the United States Food and Drug Administration in
Tellor KB, Van Tuyl JS, Armbruster AL
doaj